Status: Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Participants needed: 260
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: IDEAYA BiosciencesUpdated: Jun 23, 2026Locations: 14
Eligibility criteria
Are ≥ 18 years of age (or the minimum age of consent in accordance with local re... [+11]
Known symptomatic brain metastases requiring supraphysiologic doses of systemic... [+26]